New fibroblast activation protein inhibitor, CPD60, attenuates fibrosis and chronic liver disease progresion in CCL4 induced liver fibrosis, but not in MDR2-/- mice
单位：[1]Experimental and Translational Research Center,Beijing Friendship Hospital, Capital Medical University, Beijing, China医技科室北京市临床医学研究所实验中心首都医科大学附属北京友谊医院[2]Institute of Translational Immunology and Research Center forImmunotherapy (FZI), University Medical Center of the JohannesGutenberg-University Mainz, Mainz, Germany[3]Boehringer-Ingelheim,Cardiometabolic Research, Biberach, Germany[4]Division ofGastroenterology Beth Israel Deaconess Medical Center, HarvardMedical School Boston, Boston, United States
第一作者单位：[1]Experimental and Translational Research Center,Beijing Friendship Hospital, Capital Medical University, Beijing, China[2]Institute of Translational Immunology and Research Center forImmunotherapy (FZI), University Medical Center of the JohannesGutenberg-University Mainz, Mainz, Germany
推荐引用方式(GB/T 7714)：
Ai Ting Yang,Yong Ook Kim,Misbah Aslam,et al.New fibroblast activation protein inhibitor, CPD60, attenuates fibrosis and chronic liver disease progresion in CCL4 induced liver fibrosis, but not in MDR2-/- mice[J].JOURNAL of HEPATOLOGY.2019,70(1):E206-E206.doi:10.1016/S0618-8278(19)30384-6.
APA：
Ai Ting Yang,Yong Ook Kim,Misbah Aslam,Mariacristina Giardino,Hiroyuki Abe...&Detlef Schuppan.(2019).New fibroblast activation protein inhibitor, CPD60, attenuates fibrosis and chronic liver disease progresion in CCL4 induced liver fibrosis, but not in MDR2-/- mice.JOURNAL of HEPATOLOGY,70,(1)
MLA：
Ai Ting Yang,et al."New fibroblast activation protein inhibitor, CPD60, attenuates fibrosis and chronic liver disease progresion in CCL4 induced liver fibrosis, but not in MDR2-/- mice".JOURNAL of HEPATOLOGY 70..1(2019):E206-E206
医学